Investment Thesis
Pre-revenue biotech company burning $5M annually with severely impaired balance sheet structure: $1.3M stockholders equity against $157.2M total assets signals extreme leverage and financing vulnerability. Current cash of $12.8M provides runway of approximately 2.5 years at existing burn rate, with no revenue generation and no insider confidence signaled by zero Form 4 filings in 90 days.
Strengths
- Adequate short-term liquidity with 3.11x current ratio providing near-term cash stability
- Relatively low capital expenditure of $6.7K indicating lean R&D infrastructure
- Manageable absolute debt level of $2.2M long-term debt
Risks
- Zero revenue with negative operating cash flow of -$5M annually creates unsustainable business model without successful drug commercialization
- Critically low stockholders equity of $1.3M relative to $157.2M assets indicates balance sheet is 99% debt-financed and vulnerable to covenant defaults
- High debt-to-equity ratio of 1.79x combined with -$17.8M operating loss creates negative interest coverage and imminent refinancing risk
- Cash depletion timeline of 2.5 years at current burn rate necessitates dilutive equity raises or successful clinical milestone achievement
- No insider buying activity in past 90 days suggests management has no conviction in near-term value creation
Key Metrics to Watch
- Quarterly cash burn rate and cash runway remaining
- Clinical trial progress and milestone achievements on lead drug candidates
- Changes in stockholders equity and debt structure indicating dilutive financing events
- Operating cash flow trend and path to profitability timeline
Financial Metrics
Revenue
N/A
Net Income
-17.8M
EPS (Diluted)
$-21.28
Free Cash Flow
-5.0M
Total Assets
157.2M
Cash
12.8M
Profitability Ratios
Gross Margin
N/A
Operating Margin
N/A
Net Margin
N/A
ROE
-1,421.2%
ROA
-11.3%
FCF Margin
N/A
Balance Sheet & Liquidity
Current Ratio
3.11x
Quick Ratio
3.11x
Debt/Equity
1.79x
Debt/Assets
8.0%
Interest Coverage
-155,745.87x
Long-term Debt
2.2M
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-05-16T08:20:26.259816 |
Data as of: 2026-03-31 |
Powered by Claude AI